In final report, ICER appears to have a change of heart on new acute migraine therapies
ICER appears to have reversed course on its assessment of two acute migraine therapies.
The cost-effectiveness watchdog in November issued a draft report suggesting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
